<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40932532</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1436-3771</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>10</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>11</Day></PubDate></JournalIssue><Title>Clinical oral investigations</Title><ISOAbbreviation>Clin Oral Investig</ISOAbbreviation></Journal><ArticleTitle>Evaluation of chemerin, fetuin-A, interleukin-34, and interleukin-13 levels following periodontal treatment in diabetes mellitus.</ArticleTitle><Pagination><StartPage>448</StartPage><MedlinePgn>448</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00784-025-06539-3</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This cohort study investigated salivary and serum chemerin, fetuin-A, interleukin (IL)-34, and IL-13 changes in type 2 diabetes mellitus (T2DM) periodontitis following non-surgical periodontal therapy (NSPT).</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">A total of 110 participants were assigned to five groups (n&#x2009;=&#x2009;22 each): non-periodontitis, non-periodontitis with T2DM, periodontitis (P), well-controlled T2DM periodontitis (WDM-P), and poorly controlled T2DM periodontitis (PDM-P). Periodontal parameters were recorded and biological samples collected at baseline and/or 3&#xa0;months post-NSPT. Biomolecule levels were measured using ELISA.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All periodontitis groups improved in periodontal parameters after 3&#xa0;months (p&#x2009;&lt;&#x2009;0.05), but the proportion of patients who responded poorly to NSPT was higher in the PDM-P group compared to the P group (p&#x2009;=&#x2009;0.026). HbA1c decreased in WDM-P and PDM-P groups at 3&#xa0;months (p&#x2009;&lt;&#x2009;0.05). All salivary biomolecules were individually associated with periodontitis (p&#x2009;&lt;&#x2009;0.05), and their combined model distinguished periodontitis (AUC: 0.94). Serum chemerin and fetuin-A were linked to T2DM (p&#x2009;&lt;&#x2009;0.05), and their combination predicted T2DM (AUC: 0.91). After NSPT, salivary fetuin-A increased, salivary IL-13 decreased in three periodontitis groups (p&#x2009;&lt;&#x2009;0.05), whereas salivary chemerin, IL-34, and serum IL-34 reduced only in P group (p&#x2009;&lt;&#x2009;0.05).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Salivary fetuin-A and IL-13 appear involved in periodontitis pathogenesis, while serum chemerin and fetuin-A in the T2DM. T2DM may hinder inflammation resolution, particularly involving chemerin and IL-34.</AbstractText><AbstractText Label="CLINICAL RELEVANCE" NlmCategory="CONCLUSIONS">The distinct biomolecule changes in systemically healthy versus T2DM periodontitis patients suggests that T2DM may impair inflammation resolution, underscoring the importance of personalized periodontal treatment strategies. This study was retrospectively registered on ClinicalTrials.gov (NCT06135532) on November 11, 2023.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>G&#xf6;rg&#xfc;l&#xfc;</LastName><ForeName>Nimet G&#xfc;l</ForeName><Initials>NG</Initials><AffiliationInfo><Affiliation>Department of Periodontology, Faculty of Dentistry, Marmara University, 34854, Maltepe, Istanbul, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xfc;ng&#xf6;rmek</LastName><ForeName>Hatice Selin</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Department of Periodontology, Faculty of Dentistry, Marmara University, 34854, Maltepe, Istanbul, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalkan</LastName><ForeName>Yaprak</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Esthetic Smile Academy Dental Clinic, Istanbul, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Do&#x11f;an</LastName><ForeName>Ba&#x15f;ak</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Periodontology, Faculty of Dentistry, Marmara University, 34854, Maltepe, Istanbul, T&#xfc;rkiye. basakdogan@marmara.edu.tr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT06135532</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Clin Oral Investig</MedlineTA><NlmUniqueID>9707115</NlmUniqueID><ISSNLinking>1432-6981</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D060749">alpha-2-HS-Glycoprotein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018925">Chemokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018793">Interleukin-13</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007378">Interleukins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C478630">RARRES2 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060749" MajorTopicYN="Y">alpha-2-HS-Glycoprotein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018925" MajorTopicYN="Y">Chemokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036341" MajorTopicYN="Y">Intercellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018793" MajorTopicYN="Y">Interleukin-13</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007378" MajorTopicYN="Y">Interleukins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010518" MajorTopicYN="Y">Periodontitis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012463" MajorTopicYN="N">Saliva</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Diabetes mellitus</Keyword><Keyword MajorTopicYN="N">Fetuins</Keyword><Keyword MajorTopicYN="N">Interleukins</Keyword><Keyword MajorTopicYN="N">Periodontitis</Keyword><Keyword MajorTopicYN="N">Saliva</Keyword><Keyword MajorTopicYN="N">Serum</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: This study was approved by the Clinical Research Ethics Committee of Faculty of Medicine Marmara University (protocol number: 09.2018.381). The oral and written informed consent was obtained from each participant prior to enrolment in the study. Conflict of interest statement: The authors declare no conflict of interest in the present study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>11</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>11</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>11</Day><Hour>11</Hour><Minute>6</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40932532</ArticleId><ArticleId IdType="doi">10.1007/s00784-025-06539-3</ArticleId><ArticleId IdType="pii">10.1007/s00784-025-06539-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Genco RJ, Borgnakke WS (2020) Diabetes as a potential risk for periodontitis: association studies. Periodontol 2000 83:40&#x2013;45. https://doi.org/10.1111/prd.12270</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/prd.12270</ArticleId><ArticleId IdType="pubmed">32385881</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanz M, Ceriello A, Buysschaert M, Chapple I, Demmer RT, Graziani F, Herrera D, Jepsen S, Lione L, Madianos P, Mathur M, Montanya E, Shapira L, Tonetti M, Vegh D (2018) Scientific evidence on the links between periodontal diseases and diabetes: consensus report and guidelines of the joint workshop on periodontal diseases and diabetes by the International Diabetes Federation and the European Federation of Periodontology. J Clin Periodontol 45:138&#x2013;149. https://doi.org/10.1111/jcpe.12808</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcpe.12808</ArticleId><ArticleId IdType="pubmed">29280174</ArticleId></ArticleIdList></Reference><Reference><Citation>Polak D, Sanui T, Nishimura F, Shapira L (2020) Diabetes as a risk factor for periodontal disease&#x2014;plausible mechanisms. Periodontol 2000 83:46&#x2013;58. https://doi.org/10.1111/prd.12298</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/prd.12298</ArticleId><ArticleId IdType="pubmed">32385872</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbella S, Alberti A, Donos N, Morandi B, Ercal P, Francetti L, Calciolari E (2024) Efficacy of different protocols of non-surgical periodontal therapy in patients with type 2 diabetes: a systematic review and meta-analysis. J Periodontal Res 00:1&#x2013;21. https://doi.org/10.1111/jre.13327</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jre.13327</ArticleId></ArticleIdList></Reference><Reference><Citation>Mealey BL, Ocampo GL (2007) Diabetes mellitus and periodontal disease. Periodontol 2000 44:127&#x2013;153. https://doi.org/10.1111/j.1600-0757.2006.00193.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0757.2006.00193.x</ArticleId><ArticleId IdType="pubmed">17474930</ArticleId></ArticleIdList></Reference><Reference><Citation>Morita I, Inagaki K, Nakamura F, Noguchi T, Matsubara T, Yoshii S, Nakagaki H, Mizuno K, Sheiham A, Sabbah W (2012) Relationship between periodontal status and levels of glycated hemoglobin. J Dent Res 91:161&#x2013;166. https://doi.org/10.1177/0022034511431583</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0022034511431583</ArticleId><ArticleId IdType="pubmed">22157098</ArticleId></ArticleIdList></Reference><Reference><Citation>Demmer RT, Holtfreter B, Desvarieux M, Jacobs DR Jr, Kerner W, Nauck M, V&#xf6;lzke H, Kocher T (2012) The influence of type 1 and type 2 diabetes on periodontal disease progression: prospective results from the Study of Health in Pomerania (SHIP). Diabetes Care 35:2036&#x2013;2042. https://doi.org/10.2337/dc11-2453</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc11-2453</ArticleId><ArticleId IdType="pubmed">22855731</ArticleId><ArticleId IdType="pmc">3447825</ArticleId></ArticleIdList></Reference><Reference><Citation>Preshaw PM, Taylor JJ, Jaedicke KM, De Jager M, Bikker JW, Selten W, Bissett SM, Whall KM, van de Merwe R, Areibi A, Jitprasertwong P, Al-Shahwani R, Weaver J, Taylor R, Wassall RR (2020) Treatment of periodontitis reduces systemic inflammation in type 2 diabetes. J Clin Periodontol 47(6):737&#x2013;746. https://doi.org/10.1111/jcpe.13274</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcpe.13274</ArticleId><ArticleId IdType="pubmed">32106333</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa K, Watanabe K, Mizutani K, Takeda K, Takemura S, Sakaniwa E, Mikami R, Kido D, Saito N, Kominato H, Hattori A, Iwata T (2024) Genetic analysis of impaired healing responses after periodontal therapy in type 2 diabetes: clinical and in vivo studies. J Periodontal Res 59:712&#x2013;727. https://doi.org/10.1111/jre.13249</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jre.13249</ArticleId><ArticleId IdType="pubmed">38501307</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheong ASQ, Suvan JE (2025) Considerations in the treatment of individuals with obesity and periodontitis. Clin Obes 15:e70002. https://doi.org/10.1111/cob.70002</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cob.70002</ArticleId><ArticleId IdType="pubmed">40135427</ArticleId><ArticleId IdType="pmc">12096047</ArticleId></ArticleIdList></Reference><Reference><Citation>Checa-Ros A, Hsueh WC, Merck B, Gonz&#xe1;lez-Torres H, Berm&#xfa;dez V and D&#x2019;Marco L (2024) Obesity and oral health: the link between adipokines and periodontitis. touchREV Endocrinol 20:25&#x2013;31. https://doi.org/10.17925/ee.2024.20.1.7</Citation></Reference><Reference><Citation>Stadler AF, Angst PDM, Arce RM, Gomes SC, Oppermann RV, Susin C (2016) Gingival crevicular fluid levels of cytokines/chemokines in chronic periodontitis: a meta-analysis. J Clin Periodontol 43:727&#x2013;745. https://doi.org/10.1111/jcpe.12557</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcpe.12557</ArticleId><ArticleId IdType="pubmed">27027257</ArticleId></ArticleIdList></Reference><Reference><Citation>Miranda TS, Heluy SL, Cruz DF, da Silva HDP, Feres M, Figueiredo LC, Duarte PM (2019) The ratios of pro-inflammatory to anti-inflammatory cytokines in the serum of chronic periodontitis patients with and without type 2 diabetes and/or smoking habit. Clin Oral Investig 23:641&#x2013;650. https://doi.org/10.1007/s00784-018-2471-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00784-018-2471-5</ArticleId><ArticleId IdType="pubmed">29737428</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham MN, Hawa MI, Pfleger C, Roden M, Schernthaner G, Pozzilli P, Buzzetti R, Scherbaum W, Seissler J, Kolb H, Hunter S, Leslie RDG, Schloot NC, Action LSG (2011) Pro- and anti-inflammatory cytokines in latent autoimmune diabetes in adults, type 1 and type 2 diabetes patients: Action LADA 4. Diabetologia 54:1630&#x2013;1638. https://doi.org/10.1007/s00125-011-2088-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-011-2088-6</ArticleId><ArticleId IdType="pubmed">21347621</ArticleId></ArticleIdList></Reference><Reference><Citation>Deschner J, Eick S, Damanaki A, Nokhbehsaim M (2014) The role of adipokines in periodontal infection and healing. Mol Oral Microbiol 29:258&#x2013;269. https://doi.org/10.1111/omi.12070</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/omi.12070</ArticleId><ArticleId IdType="pubmed">25052571</ArticleId></ArticleIdList></Reference><Reference><Citation>Jialal I, Pahwa R (2019) Fetuin-A is also an adipokine. Lipids Health Dis 18:73. https://doi.org/10.1186/s12944-019-1021-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12944-019-1021-8</ArticleId><ArticleId IdType="pubmed">30917813</ArticleId><ArticleId IdType="pmc">6437840</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivas PR, Wagner AS, Reddy LV, Deutsch DD, Leon MA, Goustin AS, Grunberger G (1993) Serum &#x3b1;2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol Endocrinol 7:1445&#x2013;1455. https://doi.org/10.1210/mend.7.11.7906861</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/mend.7.11.7906861</ArticleId><ArticleId IdType="pubmed">7906861</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;zcan E, Saygun NI, Serdar MA, Kurt N (2015) Evaluation of the salivary levels of visfatin, chemerin, and progranulin in periodontal inflammation. Clin Oral Investig 19:921&#x2013;928. https://doi.org/10.1007/s00784-014-1308-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00784-014-1308-0</ArticleId><ArticleId IdType="pubmed">25164155</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen MX, Zhong YJ, Dong QQ, Wong HM, Wen YF (2021) Global, regional, and national burden of severe periodontitis, 1990&#x2013;2019: an analysis of the Global Burden of Disease Study 2019. J Clin Periodontol 48:1165&#x2013;1188. https://doi.org/10.1111/jcpe.13506</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcpe.13506</ArticleId><ArticleId IdType="pubmed">34101223</ArticleId></ArticleIdList></Reference><Reference><Citation>Akgul Balaban Y, Yilmaz N, Kalayci M, Unal M, Turhan T (2019) Irisin and chemerin levels in patients with type 2 diabetes mellitus. Acta Endocrinol (Buchar) 15:442&#x2013;446. https://doi.org/10.4183/aeb.2019.442</Citation><ArticleIdList><ArticleId IdType="doi">10.4183/aeb.2019.442</ArticleId><ArticleId IdType="pubmed">32377240</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou ZW, Ju HX, Sun MZ, Chen HM, Fu QP, Jiang DM (2018) Serum fetuin-A levels in obese and non-obese subjects with and without type 2 diabetes mellitus. Clin Chim Acta 476:98&#x2013;102. https://doi.org/10.1016/j.cca.2017.11.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2017.11.023</ArticleId><ArticleId IdType="pubmed">29174342</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomathi G, Gopalakrishnan S, Sudhakar U, Raghavan A, Narayan KV, Sundaram SG and Sudhakar Sr U (2023) Effects of non-surgical periodontal therapy on saliva and gingival crevicular fluid levels of chemerin in periodontitis subjects with and without type 2 diabetes mellitus. Cureus 15. https://doi.org/10.7759/cureus.33388</Citation></Reference><Reference><Citation>Nair S, Nisha K (2022) Evaluation of the effect of scaling and root planing on salivary and serum fetuin-A levels in patients with stages II and III periodontitis. J Periodontol 93:179&#x2013;188. https://doi.org/10.1002/JPER.21-0179</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JPER.21-0179</ArticleId></ArticleIdList></Reference><Reference><Citation>Almarghlani A, Settem RP, Croft AJ, Metcalfe S, Giangreco M, Kay JG (2022) Interleukin-34 permits Porphyromonas gingivalis survival and NF-&#x3ba;B p65 inhibition in macrophages. Mol Oral Microbiol 37:109&#x2013;121. https://doi.org/10.1111/omi.12366</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/omi.12366</ArticleId><ArticleId IdType="pubmed">35576119</ArticleId><ArticleId IdType="pmc">9617590</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishikawa T, Sugawara S, Kihara H, Hanasaka T, Hatakeyama W, Sasaki M, Kondo H (2021) Titanium nanoparticles potentially affect gingival tissue through IL-13&#x3b1;2 receptor expression. J Oral Sci 63:263&#x2013;266. https://doi.org/10.2334/josnusd.21-0130</Citation><ArticleIdList><ArticleId IdType="doi">10.2334/josnusd.21-0130</ArticleId><ArticleId IdType="pubmed">34039830</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Mansoori L, Al-Jaber H, Prince MS, Elrayess MA (2022) Role of inflammatory cytokines, growth factors and adipokines in adipogenesis and insulin resistance. Inflammation 45:31&#x2013;44. https://doi.org/10.1007/s10753-021-01559-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-021-01559-z</ArticleId><ArticleId IdType="pubmed">34536157</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostafa TM, El-Gharbawy NM, Werida RH (2021) Circulating IRAPe, Irisin, and IL-34 in relation to insulin resistance in patients with type 2 diabetes. Clin Ther 43:e230&#x2013;e240. https://doi.org/10.1016/j.clinthera.2021.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2021.05.003</ArticleId><ArticleId IdType="pubmed">34103176</ArticleId></ArticleIdList></Reference><Reference><Citation>Ar&#x131;kan V, G&#xf6;rg&#xfc;l&#xfc; NG and Do&#x11f;an B (2023) Clinical and biochemical effects of smoking on non-surgical periodontal treatment in grade III stage C periodontitis patients. Clin Exp Health Sci 13:218&#x2013;227. https://doi.org/10.33808/clinexphealthsci.1128101</Citation></Reference><Reference><Citation>G&#xf6;rg&#xfc;l&#xfc; NG, Do&#x11f;an B (2022) Effect of non-surgical periodontal treatment on salivary and serum biomarkers in stage III grade B and C periodontitis. J Periodontol 93:1191&#x2013;1205. https://doi.org/10.1002/JPER.21-0536</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JPER.21-0536</ArticleId><ArticleId IdType="pubmed">35043972</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xfc;tti S, Howald C, Arous C, Dermitzakis E, Halban PA, Bouzakri K (2016) IL-13 improves beta-cell survival and protects against IL-1beta-induced beta-cell death. Mol Metab 5:122&#x2013;131. https://doi.org/10.1016/j.molmet.2015.11.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmet.2015.11.003</ArticleId><ArticleId IdType="pubmed">26909320</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist P, Lundberg P, Persson E, Johansson A, Lundgren I, Lie A, Conaway HH, Lerner UH (2006) Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway. J Biol Chem 281:2414&#x2013;2429. https://doi.org/10.1074/jbc.M510160200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M510160200</ArticleId><ArticleId IdType="pubmed">16251181</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Reyes CP, G&#xf3;mez-Arauz AY, Torres-Castro I, Manjarrez-Reyna AN, Palomera LF, Olivos-Garc&#xed;a A, Mendoza-Tenorio E, S&#xe1;nchez-Medina GA, Islas-Andrade S, Melendez-Mier G, Escobedo G (2018) Serum levels of interleukin-13 increase in subjects with insulin resistance but do not correlate with markers of low-grade systemic inflammation. J Diabetes Res. https://doi.org/10.1155/2018/7209872</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/7209872</ArticleId><ArticleId IdType="pubmed">29675435</ArticleId><ArticleId IdType="pmc">5841096</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramseier CA, Kinney JS, Herr AE, Braun T, Sugai JV, Shelburne CA, Rayburn LA, Tran HM, Singh AK, Giannobile WV (2009) Identification of pathogen and host-response markers correlated with periodontal disease. J Periodontol 80:436&#x2013;446. https://doi.org/10.1902/jop.2009.080480</Citation><ArticleIdList><ArticleId IdType="doi">10.1902/jop.2009.080480</ArticleId><ArticleId IdType="pubmed">19254128</ArticleId><ArticleId IdType="pmc">5695217</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonetti MS, Greenwell H, Kornman KS (2018) Staging and grading of periodontitis: framework and proposal of a new classification and case definition. J Periodontol 89(Suppl 1):159&#x2013;172. https://doi.org/10.1002/JPER.18-0006</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JPER.18-0006</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang NP, Bartold PM (2018) Periodontal health. J Periodontol 89(Suppl 1):9&#x2013;16. https://doi.org/10.1002/JPER.16-0517</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JPER.16-0517</ArticleId></ArticleIdList></Reference><Reference><Citation>Silness J, L&#xf6;e H (1964) Periodontal disease in pregnancy part II. Correlation between oral hygiene and periodontal condition. Acta Odontol Scand 22:121&#x2013;135. https://doi.org/10.3109/00016356408993968</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00016356408993968</ArticleId><ArticleId IdType="pubmed">14158464</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf6;e H, Silness J (1963) Periodontal disease in pregnancy I. prevalence and severity. Acta Odontol Scand 21:533&#x2013;551. https://doi.org/10.3109/00016356309011240</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00016356309011240</ArticleId><ArticleId IdType="pubmed">14121956</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmlund A, Lind L (2021) Periodontal disease and a poor response to periodontal treatment were associated with an increased risk of incident diabetes: a longitudinal cohort study in Sweden. J Clin Periodontol 48:1605&#x2013;1612. https://doi.org/10.1111/jcpe.13558</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcpe.13558</ArticleId><ArticleId IdType="pubmed">34605049</ArticleId></ArticleIdList></Reference><Reference><Citation>Madianos PN, Koromantzos PA (2018) An update of the evidence on the potential impact of periodontal therapy on diabetes outcomes. J Clin Periodontol 45:188&#x2013;195. https://doi.org/10.1111/jcpe.12836</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcpe.12836</ArticleId><ArticleId IdType="pubmed">29277978</ArticleId></ArticleIdList></Reference><Reference><Citation>Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N (2004) Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 141:413&#x2013;420. https://doi.org/10.7326/0003-4819-141-6-200409210-00006</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-141-6-200409210-00006</ArticleId><ArticleId IdType="pubmed">15381514</ArticleId></ArticleIdList></Reference><Reference><Citation>Karde&#x15f;ler L, Buduneli N, &#xc7;etinkalp &#x15e;, Kinane DF (2010) Adipokines and inflammatory mediators after initial periodontal treatment in patients with type 2 diabetes and chronic periodontitis. J Periodontol 81:24&#x2013;33. https://doi.org/10.1902/jop.2009.090267</Citation><ArticleIdList><ArticleId IdType="doi">10.1902/jop.2009.090267</ArticleId><ArticleId IdType="pubmed">20059414</ArticleId></ArticleIdList></Reference><Reference><Citation>Gon&#xe7;alves D, Correa FOB, Khalil NM, De Faria Oliveira OMM, Orrico SRP (2008) The effect of non-surgical periodontal therapy on peroxidase activity in diabetic patients: a case&#x2013;control pilot study. J Clin Periodontol 35:799&#x2013;806. https://doi.org/10.1111/j.1600-051X.2008.01289.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-051X.2008.01289.x</ArticleId><ArticleId IdType="pubmed">18651848</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Liu Y, Liu S, Gao M, Wang W, Chen K, Huang L, Liu Y (2023) Diabetic vascular diseases: molecular mechanisms and therapeutic strategies. Signal Transduct Target Ther 8:152. https://doi.org/10.1038/s41392-023-01400-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-023-01400-z</ArticleId><ArticleId IdType="pubmed">37037849</ArticleId><ArticleId IdType="pmc">10086073</ArticleId></ArticleIdList></Reference><Reference><Citation>Beklen A (2017) Effects of IL-13 on TGF-&#x3b2; and MMP-1 in periodontitis. Biotech Histochem 92:374&#x2013;380. https://doi.org/10.1080/10520295.2017.1312526</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10520295.2017.1312526</ArticleId><ArticleId IdType="pubmed">28682139</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Wei Z, Xia T, Shi B (2021) Microrna-146a downregulates interleukin-13 and inhibits the proliferation of human periodontal ligament stem cells. Arch Oral Biol 129:105165. https://doi.org/10.1016/j.archoralbio.2021.105165</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.archoralbio.2021.105165</ArticleId><ArticleId IdType="pubmed">34146927</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajoui O, Janani R, Tulic M, Joubert P, Ronis T, Hamid Q, Zheng H, Mazer BD (2004) Synthesis of IL-13 by human B lymphocytes: regulation and role in IgE production. J Allergy Clin Immunol 114:657&#x2013;663. https://doi.org/10.1016/j.jaci.2004.05.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2004.05.034</ArticleId><ArticleId IdType="pubmed">15356573</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X, Lin X, Seliger AR, Eastcott J, Kawai T, Taubman MA (2009) Expression of receptor activator of nuclear factor-&#x3ba;B ligand by B cells in response to oral bacteria. Oral Microbiol Immunol 24:190&#x2013;196. https://doi.org/10.1111/j.1399-302X.2008.00494.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-302X.2008.00494.x</ArticleId><ArticleId IdType="pubmed">19416447</ArticleId><ArticleId IdType="pmc">2692067</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatanaka E, Monteagudo PT, Marrocos MS, Campa A (2006) Neutrophils and monocytes as potentially important sources of proinflammatory cytokines in diabetes. Clin Exp Immunol 146:443&#x2013;447. https://doi.org/10.1111/j.1365-2249.2006.03229.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2006.03229.x</ArticleId><ArticleId IdType="pubmed">17100763</ArticleId><ArticleId IdType="pmc">1810405</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo VY, Cao B, Cai C, Cheng KK, Cheung BMY (2018) Fetuin-A levels and risk of type 2 diabetes mellitus: a systematic review and meta-analysis. Acta Diabetol 55:87&#x2013;98. https://doi.org/10.1007/s00592-017-1068-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00592-017-1068-9</ArticleId><ArticleId IdType="pubmed">29127490</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xe9;niz A, Gonz&#xe1;lez M, Besn&#xe9; I, Carr-Ugarte H, G&#xf3;mez- Garc&#xed;a I, Portillo MP (2022) Role of chemerin in the control of glucose homeostasis. Mol Cell Endocrinol 541:111504. https://doi.org/10.1016/j.mce.2021.111504</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mce.2021.111504</ArticleId><ArticleId IdType="pubmed">34763009</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathews ST, Rakhade S, Zhou X, Parker GC, Coscina DV, Grunberger G (2006) Fetuin-null mice are protected against obesity and insulin resistance associated with aging. Biochem Biophys Res Commun 350:437&#x2013;443. https://doi.org/10.1016/j.bbrc.2006.09.071</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.09.071</ArticleId><ArticleId IdType="pubmed">17011519</ArticleId></ArticleIdList></Reference><Reference><Citation>Pal D, Dasgupta S, Kundu R, Maitra S, Das G, Mukhopadhyay S, Ray S, Majumdar SS, Bhattacharya S (2012) Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med 18:1279&#x2013;1285. https://doi.org/10.1038/nm.2851</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2851</ArticleId><ArticleId IdType="pubmed">22842477</ArticleId></ArticleIdList></Reference><Reference><Citation>Sell H, Laurencikiene J, Taube A, Eckardt K, Cramer A, Horrighs A, Arner P, Eckel J (2009) Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells. Diabetes 58:2731&#x2013;2740. https://doi.org/10.2337/db09-0277</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db09-0277</ArticleId><ArticleId IdType="pubmed">19720798</ArticleId><ArticleId IdType="pmc">2780878</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazzaruso C, Montalcini T, Gallotti P, Ferrulli A, Massa Saluzzo C, Pujia A, Luzi L, Coppola A (2023) Impact of microvascular complications on the outcomes of diabetic foot in type 2 diabetic patients with documented peripheral artery disease. Endocrine 80:71&#x2013;78. https://doi.org/10.1007/s12020-022-03291-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12020-022-03291-6</ArticleId><ArticleId IdType="pubmed">36565405</ArticleId></ArticleIdList></Reference><Reference><Citation>Samanta S (2021) Glycated hemoglobin and subsequent risk of microvascular and macrovascular complications. Indian J Med Sci 73:230&#x2013;238. https://doi.org/10.25259/IJMS_16_2020</Citation><ArticleIdList><ArticleId IdType="doi">10.25259/IJMS_16_2020</ArticleId></ArticleIdList></Reference><Reference><Citation>Yilmaz A, Yilmaz T, Gunay M (2018) Elevated serum fetuin-A levels are associated with grades of retinopathy in type 2 diabetic patients. Int Ophthalmol 38:2445&#x2013;2450. https://doi.org/10.1007/s10792-017-0750-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10792-017-0750-9</ArticleId><ArticleId IdType="pubmed">29071522</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu P, Wang W, Yao Y, Xu Y, Wang L, Zang P, Ma J, Yang C, Liang J, Lu B, Shao J (2019) Increased circulating chemerin in relation to chronic microvascular complications in patients with type 2 diabetes. Int J Endocrinol. https://doi.org/10.1155/2019/8693516</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/8693516</ArticleId><ArticleId IdType="pubmed">31379940</ArticleId><ArticleId IdType="pmc">6662434</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalsi AS, Bomfim DI, Hussain Z (2019) Factors affecting decision making at reassessment of periodontitis. Part 1: history and examination at reassessment. Br Dent J 227:673&#x2013;680. https://doi.org/10.1038/s41415-019-0850-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41415-019-0850-1</ArticleId><ArticleId IdType="pubmed">31653999</ArticleId></ArticleIdList></Reference><Reference><Citation>Patern&#xf2; Holtzman L, Valente NA, Vittorini Orgeas G, Copes L, Discepoli N, Clementini M (2025) Change in clinical parameters after subgingival instrumentation for the treatment of periodontitis and timing of periodontal re-evaluation: a systematic review and meta-analysis. J Clin Periodontol 52:137&#x2013;158. https://doi.org/10.1111/jcpe.13985</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcpe.13985</ArticleId><ArticleId IdType="pubmed">38706227</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>